Tag : ORION10

Neurology

ORION-10: 58% Reduction in LDL With Inclisiran

Newsemia
A second phase 3 study has shown impressive reductions in LDL on top of statins with this novel agent given just twice a year. Medscape...
Latest News

The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

Newsemia
PHILADELPHIA–(BUSINESS WIRE)—- $MDCO #ASCVD–The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy